Genmab Expands Share Capital through Employee Warrant Exercise
Genmab Achieves Capital Increase Through Warrant Exercise
Company Announcement
On June 17, 2025, Genmab A/S (NASDAQ: GMAB) has made a pivotal announcement that marks a significant increase in its share capital.
The company is set to increase its share capital by 32,117 shares, a result attributed to the exercise of employee warrants. This development not only highlights Genmab's commitment to its employees but also reflects its growth-oriented strategy.
Details of the Capital Increase
The capital increase will occur without preemption rights being offered to existing shareholders, making it a unique opportunity for the company to capitalize without maintaining proportionality among stakeholding. The shares are subscribed in cash, generating proceeds of approximately DKK 33.3 million.
Here is how the shares break down according to their subscription prices:
- 27,396 shares at DKK 1,025.00
- 2,790 shares at DKK 1,050.00
- 150 shares at DKK 1,147.50
- 1,557 shares at DKK 1,161.00
- 224 shares at DKK 1,334.50
Implications for Company Shares and Value
As a result of this increase, the share capital of Genmab will now total DKK 64,154,254, consisting of 64,154,254 shares with a nominal value of DKK 1 each. This change corresponds to 64,154,254 votes within the company structure. All newly issued shares are ordinary shares that offer the same rights in terms of dividends and other corporate benefits.
With this influx of capital, Genmab is poised to continue its mission towards enhancing the lives of patients through innovative therapies. The shares will be officially traded on Nasdaq Copenhagen once the necessary registrations with the Danish Business Authority are completed.
Genmab: Striving for Innovative Biotherapeutics
About Genmab
Genmab is a leading international biotechnology enterprise devoted to improving patient lives through cutting-edge antibody therapeutics. Having established its presence in 1999, the company maintains a base in Copenhagen and operates globally across North America, Europe, and Asia Pacific.
With over two decades of pioneering work, Genmab emphasizes collaboration, innovation, and a knack for formulating next-generation antibody technology platforms. The company’s proprietary pipeline encompasses bispecific T-cell engagers, next-generation immune checkpoint modulators, and highly evolved antibody-drug conjugates among others.
The vision for Genmab by 2030 is clear: to transform cancer treatment through top-tier antibody medicines that set new standards in therapeutic efficacy.
Contact Information for Inquiries
For any inquiries related to this capital increase, you can reach out to:
Marisol Peron
Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen
Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What does the capital increase mean for Genmab's shareholders?
The capital increase represents an opportunity for Genmab to raise additional funds without diluting existing shareholders' equity, as the shares are issued without preemptive rights.
How many new shares is Genmab issuing?
Genmab is increasing its share capital by 32,117 new shares as a direct result of the exercise of employee warrants.
What will happen to the new shares once issued?
The new shares will be listed on Nasdaq Copenhagen and will provide rights to dividends and other benefits associated with ordinary shares.
How much money will Genmab gain from this capital increase?
The proceeds from the capital increase are expected to be approximately DKK 33.3 million, which will aid the company's ongoing projects and initiatives.
What is Genmab's long-term vision?
Genmab aims to revolutionize cancer treatment and improve patient outcomes through innovative and effective antibody treatments by the year 2030.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.